ISRCTN24921472终止1 期
Phase I/II study of oral MEK inhibitor selumetinib (AZD6244 hyd-sulphate) in combination with highly active anti retroviral therapy (HAART) in AIDS-associated Kaposi's sarcoma (KS)
Sheffield Teaching Hospitals NHS Trust (UK)0 个研究点目标入组 19 人开始时间: 2012年3月2日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 终止
- 发起方
- 入组人数
- 19
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •1. Human immunodeficiency virus (HIV) positive and established on a HAART regimen for >=3 months
- •2. Histologically confirmed KS
- •3. Measurable disease according to AIDS Clinical Trials Group (ACTG) criteria
- •4. Evidence of disease progression in the past 6 months, without anticancer treatment since progression
- •5. Progressive cutaneous or nodal KS not requiring chemotherapy or progressive KS following cytotoxic chemotherapy
- •6. Adequate haematological function:
- •6.1. Haemoglobin = 9 g/dL
- •6.2. Absolute neutrophil count = 1.5 x 10 9/L
- •6.3. Platelets = 100 x 10 9/L
- •7. Adequate hepatic function:
- •7.1. Serum bilirubin = 1.5 x upper limit of normal (ULN)
- •7.2. Alanine aminotransferase (ALT) = 2.5 x ULN
- •7.3. Aspartate aminotransferase (AST) = 2.5 x ULN
- •8. Adequate renal function:
- •8.1. Serum creatinine clearance > 50 ml/min (Cockcroft-Gault formula or 24 hour urine collection)
- •8.2. Left ventricular function >50% normal
- •9. Age = 18 years.
- •10. Eastern Cooperative Oncology Group (ECOG) performance status > 2
- •11. For selumetinib, women of child bearing age and child bearing potential must have a negative pregnancy test prior to study entry and be using an adequate contraception method, which must be continued while on treatment and for at least 4 weeks after the study treatment has ended
- •12. Male patients must agree to use an effective contraception method while on treatment and for at least 16 weeks after the study treatment has ended (barrier contraception is recommended for all individuals living with HIV).
- •13. Written informed consent
排除标准
- •1. HIV viral load > 200 copies/ml
- •2. Any previous treatment with a Ras, Raf or MEK inhibitor
- •3. Active opportunistic infections.
- •4. Known hepatitis B, hepatitis C
- •5. Clinical evidence of uncontrolled hypertension (systolic BP > 150 mmHg or diastolic BP > 90 mmHg on 2 readings = 1 hour apart))
- •6. Clinical evidence of heart failure (= New York Heart Association [NYHA] Class II)
- •7. Clinical evidence of atrial fibrillation (heart rate > 100 bpm) or unstable ischaemic heart disease (MI within 6 months prior to starting treatment or angina requiring the use of nitrates > once weekly)
- •8. Major surgery within 4 weeks prior to starting selumetinib
- •9. Evidence of any psychological, familial, sociological or geographical condition potentially hampering protocol compliance
- •10. Clinical judgement by the Investigator that the patient should not participate in the study
- •11. Refractory nausea, vomiting, chronic gastrointestinal diseases (e.g. inflammatory bowel disease) or significant bowel resection that would preclude adequate absorption
- •12. Treatment with any investigational product within 28 days of registration
- •13. Pregnant or breastfeeding women
研究者
相似试验
进行中（未招募）
1 期
A phase I/II trial of selumetinib in combination with anti-retroviral therapy for AIDS-associated Kaposi's sarcomaEUCTR2011-003099-35-GBSheffield Teaching Hospitals NHS Foundation Trust37
招募中
1 期
Early Phase Study Evaluating MEK and MDM2 Inhibition in Patients With NF1 and MPNSTMalignant Peripheral Nerve Sheath Tumor (MPNST)Neurofibromatosis 1 (NF1)Atypical NeurofibromaNCT06735820AeRang Kim45
已完成
2 期
Selumetinib in Cancers With BRAF MutationsAdult Solid NeoplasmNCT00888134National Cancer Institute (NCI)28
招募中
1 期
Selumetinib and Azacitidine in High Risk Chronic Blood CancersChronic Myeloid LeukemiaMyelofibrosesNCT03326310University of Chicago18
已完成
1 期
ABC-04 a Study of Cisplatin, Gemcitabine and Selumetinib in Patients With Advanced Biliary Tract CancerBiliary Tract NeoplasmsGallbladder NeoplasmsCholangiocarcinomaNCT01242605University College, London13